EDGAR Filing Documents for 0001047469-20-000944

Form 424B5 - Prospectus [Rule 424(b)(5)]:

SEC Accession No. 0001047469-20-000944

Filing Date

2020-02-19

Accepted

2020-02-19 17:28:23

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	424B5	a2240748z424b5.htm	424B5	554710
2	G261620.JPG	g261620.jpg	GRAPHIC	20049
3	G797372.JPG	g797372.jpg	GRAPHIC	22046
4	G178942.JPG	g178942.jpg	GRAPHIC	25876
	Complete submission text file	0001047469-20-000944.txt		650012

Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036

Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708

Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 424B5 | Act: 33 | File No.: 333-215387 | Film No.: 20631336
SIC: 2834 Pharmaceutical Preparations